Collodion-like membrane in a newborn exposed to infliximab

Offiah, Maureen; Campbell, Leigh; Wyatt, Julie P.

doi:10.1016/j.jaad.2014.01.856

Cited by 14 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 13 There has been a case report of CB secondary to ingestion of drugs like infliximab. 14 The biopsy of the skin is nonspecific and shows compact and thickened stratum corneum. 15 …”

Section: Discussionmentioning

confidence: 99%

Collodion Baby with TGM1 gene mutation

Sharma¹,

Gupta²,

Shastri³

et al. 2015

IMCRJ

View full text Add to dashboard Cite

Collodion baby (CB) is normally diagnosed at the time of birth and refers to a newborn infant that is delivered with a lambskin-like membrane encompassing the total body surface. CB is not a specific disease entity, but is a common phenotype in conditions like harlequin ichthyosis, lamellar ichthyosis, nonbullous congenital ichthyosiform erythroderma, and trichothiodystrophy. We report a CB that was brought to our department and later diagnosed to have TGM1 gene c.984+1G>A mutation. However, it could not be ascertained whether the infant had lamellar ichthyosis or congenital ichthyosiform erythroderma (both having the same mutation). The infant was lost to follow-up.

show abstract

“… 13 There has been a case report of CB secondary to ingestion of drugs like infliximab. 14 The biopsy of the skin is nonspecific and shows compact and thickened stratum corneum. 15 …”

Section: Discussionmentioning

confidence: 99%

Collodion Baby with TGM1 gene mutation

Sharma¹,

Gupta²,

Shastri³

et al. 2015

IMCRJ

View full text Add to dashboard Cite

show abstract

“…The manufacturers of both certolizumab‐pegol and adalimumab state no objection to the use of these substances during lactation [131, 137]. Despite similarly positive indications for etanercept and infliximab, the manufacturers do not address this issue [143]. Live vaccines are not recommended for breast‐fed infants of women treated with infliximab until breast‐feeding has been discontinued for six months, unless infliximab cannot be detected in the infant’s serum.…”

Section: Systemic Treatmentmentioning

confidence: 99%

“…Additionally, in the phase 2 and 3 clinical trials, which reported 31 pregnancies, there was no evidence of teratogenicity or further fetal risks among the followed pregnancies (exact number not specified in the publication) [156]. There have also been reports on 29 psoriasis patients (with 34 pregnancies) exposed to ustekinumab; no teratogenic effects were seen (Table S5, online supporting information) [76, 138, 139, 142, 143, 156–163]. With the limited data currently available, the SmPC recommends avoiding the substance if possible during pregnancy as a precaution [164].…”

Section: Systemic Treatmentmentioning

confidence: 99%

Therapy of psoriasis during pregnancy and breast‐feeding

Gerdes

Beissert

Ochsendorf

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary There have been multiple systemic drugs approved for the therapy of psoriasis vulgaris and psoriasis arthritis (PsA) in the last decade. However, treatment decisions are difficult to make in women planning a pregnancy and in pregnant and lactating women due to the paucity of data for such cases. The strongest evidence for psoriasis therapy during pregnancy exists for topical corticosteroids. Medically controlled use of UVB‐therapy is also considered safe. The best evidence regarding systemic therapy during pregnancy and lactation is available for the group of TNF‐alpha inhibitors, which is also reflected in the respective medical product information. This is especially important in cases of psoriatic arthritis. Among traditional systemic therapeutics, the largest clinical experience exists for ciclosporin, which, if medically necessary, may be continued during gestation. However, TNF‐alpha inhibitors, especially the pegylated form, should be preferred in case of pregnancy. Furthermore, an elective pregnancy termination is not necessary due to systemic therapy of psoriasis with many further substances during the first pregnancy weeks. The current work provides a comprehensive review of the scientific literature on treatment of psoriasis during pregnancy and lactation. Based on the available scientific information, severity of psoriasis and patient’s comorbidities, the best possible therapeutic approach can be found in consensus with the patient.

show abstract

“…Similarly, the tumour necrosis factor (TNF)‐alpha inhibitor infliximab, used by a pregnant mother with severe psoriasis and psoriatic arthritis, was linked to a collodion membrane‐like phenotype in her newborn 78 . Other cutaneous features of familial ichthyosis were absent (e.g.…”

Section: Drug‐inducedmentioning

confidence: 99%

Acquired ichthyosis, asteatotic dermatitis or xerosis? An update on pathoetiology and drug‐induced associations

Park

Saeidian

Youssefian

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Acquired ichthyosis (AI) or conditions mimicking ichthyosis have been documented for well over a century. AI is limited to the skin, but can be the first presenting sign of an underlying disease or an adverse effect of select medications or environmental exposures. 1,2 Most heritable ichthyoses, with the exceptions of late-onset ichthyosis vulgaris (IV) and Refsum disease, typically manifest between the immediate postnatal period and 5 years of age. 2 AI, however, does not follow an obvious age distribution; rather, the appearance and disappearance of AI tend to coincide with onset and resolution of an inciting factor. Clinically, AI closely resembles IV with diffuse, symmetrically distributed, white-to-brown scales which can be confused with severe cases of xerosis or eczema (Figure 1a-c). 1 Histopathology of AI usually shows varying degrees of orthohyperkeratosis, a uniformly diminished or absent granular layer, and lack of dermal inflammation. 1,3 In patients with suspected AI, a detailed investigation into the clinical course typically does not yield personal or family history of ichthyosis, atopy, keratosis pilaris or other keratodermaassociated phenotypes seen with the heritable ichthyoses. 1,2 In this article, we provide an up-to-date overview of AI and the pathomechanisms suggested in the literature. While the associated clinical features in many cases of AI are unknown, detailed examples are provided for the medical conditions, medications and exposures with clinical importance. In

show abstract

Collodion-like membrane in a newborn exposed to infliximab

Cited by 14 publications

References 6 publications

Collodion Baby with TGM1 gene mutation

Collodion Baby with TGM1 gene mutation

Therapy of psoriasis during pregnancy and breast‐feeding

Acquired ichthyosis, asteatotic dermatitis or xerosis? An update on pathoetiology and drug‐induced associations

Contact Info

Product

Resources

About